PD-0436: Long-term bowel and bladder symptoms after pelvic radiotherapy or vaginal brachytherapy in the PORTEC-2 trial

3rd ESTRO Forum 2015 S213 (ABS).Data regarding tumour, treatment technique and patient-related features was collected, as well as recurrence and survival rates.Results: Median follow-up time was 35,1 months, 46 patients underwent HDR and 35 a PDR technique either with metal needles or flexible plastic catheters using a template-based system.75 were suitable for guideline stratification (2 patients lost to follow-up and 6 without complete information about risk factors).According to the ASTRO CS, 47 patients were considered 'suitable', 23 'cautionary' and 5 'unsuitable'.According to GEC-ESTRO, 60 were 'low risk', 7 'intermediate risk' and 8 'high risk'.69 patients were defined as 'acceptable' and 6 as 'not acceptable' following ABS recommendations.46 of ABS 'acceptable' patients were also either 'suitable' or 'low risk' according to ASTRO and GEC-ESTRO, meaning an accordance rate between guidelines on who to definitely treat with APBI of 67%.6% (n=4) of patients with clear indication not to treat by ASTRO and/or GEC-ESTRO fitted the 'acceptable' group criteria by ABS.No locoregional relapses were documented, 1 patient developed distant metastasis.Conclusions: This study shows a lack of agreement between the current guidelines and supports the existing evidence that APBI with multicatheter brachytherapy is an effective adjuvant treatment modality.